Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Roivant acquires a Glaxo Alzheimer’s compound

05 Jan 2021

Executive Summary

Roivant Sciences Ltd., via its wholly owned subsidiary Roivant Neurosciences Ltd., acquired GlaxoSmithKline PLC's Phase II SB742457 (GSK742457), a selective 5-HT6 antagonist for cognitive and other functional defects in neurological diseases. NOTES: Roivant Neurosciences is now called Axovant Sciences Ltd. and SB742457 was renamed RVT101.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product Purchase
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By